BioNTech will close its vaccine manufacturing plant in Singapore by February next year.

German biotechnology company BioNTech confirmed on April 2 local time that it will close its vaccine and drug manufacturing plant in Singapore by February 2027 to ensure that production capacity is in line with clinical product portfolios and long-term strategic directions. The decision will affect 85 employees. BioNTech stated that there are currently no plans to establish any other offices in Singapore after the closure of the plant.